Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enigma gains PCR patents:

This article was originally published in Clinica

Executive Summary

Enigma Diagnostics has gained 25 patents and patent applications from the UK's Defence Science and Technology Laboratory (Dstl) after signing an exclusive licensing deal. The patents relate to a broad range of real-time PCR technologies in development, including Pyrostart, ResonSense and Temperature Control. The PCR systems are being developed for the real-time detection and identification of infectious organisms in clinical, environmental and biological samples. Under the agreement, Porton Down, UK-based Enigma will be able to develop its own patent portfolio with any improvement that is made to the technologies. It will also enable the company to sub-license the technologies for PCR and non-PCR applications. The patents, which were previously the responsibility of Dstl, are managed by Enigma with effect from August 13. The licence agreement will remain in place until 2026.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel